Advertisement

Table of contents

  1. Front Matter
    Pages i-viii
  2. Cornelius F. Waller
    Pages 1-27
  3. Markus Lindauer, Andreas Hochhaus
    Pages 29-68
  4. Martin Gresse, Theo D. Kim, Philipp le Coutre
    Pages 69-85
  5. Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf, Dominik Wolf
    Pages 87-108
  6. Julius Wehrle, Nikolas von Bubnoff
    Pages 109-118
  7. Stefanie Ajayi, Heiko Becker, Heike Reinhardt, Monika Engelhardt, Robert Zeiser, Nikolas von Bubnoff et al.
    Pages 119-132
  8. Andriani Charalambous, Mark-Alexander Schwarzbich, Mathias Witzens-Harig
    Pages 133-168
  9. Monika Engelhardt, Stefanie Ajayi, Heike Reinhardt, Stefan Jürgen Müller, Sandra Maria Dold, Ralph Wäsch
    Pages 169-185
  10. Alwin Krämer, Tilmann Bochtler
    Pages 187-197
  11. Annika Scheffold, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
    Pages 215-242
  12. Katja Zirlik, Hendrik Veelken
    Pages 243-264
  13. Monika Engelhardt, Magdalena Szymaniak-Vits, Stefanie Ajayi, Sandra Maria Dold, Stefan Jürgen Müller, Sophia Scheubeck et al.
    Pages 265-283
  14. Katharina Kriegsmann, Mark Kriegsmann, Mathias Witzens-Harig
    Pages 285-294

About this book

Introduction

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
 
Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. 

Keywords

Small Molecules Molecular Mechanisms of Cancer Targeted Therapy Personalized Cancer Therapy Protein Tyrosine Kinease Inhibitors mTOR Proteasome Chemical Structurs Drug Interactions Treatment Applications

Editors and affiliations

  • Uwe M. Martens
    • 1
  1. 1.MOLIT InstituteCancer Center Heilbronn-Franken, SLK-ClinicsHeilbronnGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-91439-8
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-91438-1
  • Online ISBN 978-3-319-91439-8
  • Series Print ISSN 0080-0015
  • Series Online ISSN 2197-6767
  • Buy this book on publisher's site